AMENDMENT No. 2 TO CONSULTING AGREEMENTConsulting Agreement • February 23rd, 2023 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
THIS AMENDMENT No. 1 TO CONSULTING AGREEMENT (“Amendment No. 1”) is effective as of March 3, 2023 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at 421 Kipling Street, Palo Alto, California 94301, and Frank McCormick (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
AMENDMENT No. 1 TO CONSULTING AGREEMENTConsulting Agreement • February 23rd, 2023 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
THIS AMENDMENT No. 1 TO CONSULTING AGREEMENT (“Amendment No. 1”) is effective as of March 3, 2022 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at 421 Kipling Street, Palo Alto, California 94301, and Frank McCormick (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 23rd, 2023 • BridgeBio Pharma, Inc. • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT is made and dated as of November 30, 2022 (this “Second Amendment”) by and among BRIDGEBIO PHARMA, INC., a Delaware corporation (“Borrower”), each other Person party hereto as a guarantor (each a “Guarantor” and collectively, the “Guarantors”), the several banks and other financial institutions or entities party hereto (individually or collectively, as the context requires, “Lender” or “Lenders”) and U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, in its capacity as administrative agent for the Lenders (in such capacity, together with its successors in such capacity, “Administrative Agent”) and collateral agent for the Secured Parties (in such capacity, together with its successors in such capacity, “Collateral Agent”, and together with the Administrative Agent, the “Agents”).
CONSULTING AGREEMENTConsulting Agreement • February 23rd, 2023 • BridgeBio Pharma, Inc. • Pharmaceutical preparations
This Consulting Agreement (the “Agreement”) is effective as of January 1, 2021 (the “Effective Date”), and is made by and between Frank McCormick (“Consultant”), an individual located at [***] (“Company”), a Delaware corporation located at 421 Kipling Street, Palo Alto, California 94301, on behalf of itself and its Affiliates (as defined below), each a “Party” and collectively the “Parties.” The Parties hereby agree as follows.
